Zurich-Schlieren, Switzerland, November 10, 2020. TOPADUR Pharma AG, a biopharmaceutical start-up company today announces positive results from an analysis of the first two dose groups of the ongoing Phase 1 clinical of TOP-N53, a first-in-class wound healing drug candidate. The safety results from this interim analysis of the first two dose groups suggest that the drug was safe and well-tolerated. Moreover, data from the first two groups demonstrated an increase in skin microcirculation.
“These first results support the important role of TOP-N53 in the treatment of chronic wounds exemplified by diabetic foot ulcer (DFU) and digital ulcers (DU)”, said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG.
EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.Read more